Overview

Open-Label, 48 Week Extension Study of Elvucitabine in Combination With Background ART For Subjects Who Have Completed Study ACH443-014A

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
0
Participant gender:
All
Summary
To assess the safety of 48 weeks of treatment with 10 mg of elvucitabine in combination with background ART in subjects who completed protocol ACH443-014A and meet the inclusion and exclusion criteria.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Achillion Pharmaceuticals
Alexion Pharmaceuticals
Treatments:
Anti-Retroviral Agents
Dexelvucitabine
Emtricitabine
Lamivudine
Criteria
Inclusion Criteria:

- Subjects who have completed 14 days of treatment in ACH443-014A and who, in the
investigator's judgment, remain candidates to receive elvucitabine together with
background antiretroviral therapy.

Exclusion Criteria:

- Failure to meet inclusion criteria